In order to characterize exposure of the Canadian population to environmental chemicals, a human biomonitoring component has been included in the Canadian Health Measures Survey (CHMS). This nationally-representative survey, launched in 2007 by the Government of Canada, has measured over 250 chemicals in approximately 30,000 Canadians during the last decade. The capacity to interpret these data at the population level in a health risk context is gradually improving with the development of biomonitoring screening values, such as biomonitoring equivalents (BE) and human biomonitoring (HBM) values. This study evaluates recent population level biomonitoring data from the CHMS in a health risk context using biomonitoring screening values. Nationally representative biomonitoring data for fluoride, selenium, molybdenum, arsenic, silver, thallium, cyfluthrin, 2,4-dichlorophenoxyacetic acid (2,4-D), 3-phenoxybenzoic acid (3-PBA), chlorpyrifos, deltamethrin, bisphenol A, triclosan, acrylamide, cadmium, perfluorooctane sulfonate (PFOS), perfluorooctanoic acid (PFOA), bromoform, chloroform, benzene, toluene, xylene, ethylbenzene, styrene and tetrachloroethylene were screened as part as this study. For non-cancer endpoints, hazard quotients (HQs) were calculated as the ratio of population level concentrations of a specific chemical at the geometric mean and 95th percentile to the corresponding biomonitoring screening value. Cancer risks were calculated at the 5th, 25th, 50th, 75th and 95th percentiles of the population concentration using BEs based on a risk specific dose. Most of the chemicals analyzed had HQs below 1 suggesting that levels of exposure to these chemicals are not a concern at the population level. However, HQs exceeded 1 in smokers for cadmium, acrylamide and benzene, as well as in the general population for inorganic arsenic, PFOS and PFOA, 3-PBA and fluoride. Furthermore, cancer risks for inorganic arsenic, acrylamide, and benzene at most population percentiles of exposure were elevated (> 10 −5 ). Specifically, for inorganic arsenic in the general population, the HQ was 3.13 at the 95th percentile concentration and the cancer risk was 3.4 × 10 −4 at the 50th percentile of population concentrations. These results suggest that the levels of exposure in the Canadian population to some of the environmental chemicals assessed might be of concern. The results of this screening exercise support the findings of previous risk assessments and ongoing efforts to reduce risks from exposure to chemicals evaluated as part of this study. Although paucity of biomonitoring screening values for several environmental contaminants may be a limitation to this approach, our assessment contributes to the prioritization of a number of chemicals measured as part of CHMS for followup activities such as more detailed characterization of exposure sources.
Introduction
Exposure of the general population to potentially harmful environmental chemicals is a growing global concern. Biomonitoring, the direct measurement of a biomarker (a chemical or its metabolites) in biological samples such as blood or urine, is an approach used to https://doi.org/10.1016/j.ijheh.2019.07.009 Received 16 May 2019; Received in revised form 19 July 2019; Accepted 20 July 2019 measure exposures to environmental chemicals (Angerer et al., 2011; . Human biomonitoring is included as a component of the Canadian Health Measures Survey (CHMS) to address the monitoring and surveillance component of the Government of Canada's Chemicals Management Plan (Canada, 2006a; Eykelbosh et al., 2018) . The CHMS is an ongoing nationally representative survey initiated in 2007 by Statistics Canada in partnership with Health Canada and the Public Health Agency of Canada. This survey collects health and wellness data on the general population, such as weight, height, physical fitness and markers of chronic and infectious disease (Eykelbosh et al., 2018; Haines et al., 2017) . The biomonitoring component of the CHMS measures environmental chemicals in blood, urine and/or hair (Health Canada, 2017c) . The biomonitoring data have been published as summary statistics for different age and sex groups in CHMS biomonitoring reports for cycle 1 (2007-2009), cycle 2 (2009-2011), cycle 3 (2012-2013) and cycle 4 (2014) (2015) (Health Canada, 2010c , 2015b 2017c) . Collectively, the first four cycles of the CHMS have provided population-level data for over 250 environmental chemicals in Canadians aged 3-79 years.
Biomonitoring data are of significant value in exposure assessments as they provide evidence of internal exposure to a chemical from all sources, routes and pathways (Angerer et al., 2011; Clewell et al., 2008; Sexton et al., 2004) . However, a lack of appropriate health-based screening values for the general population may impede the interpretation of these biological measures in a health risk context (Hays et al., 2007) . Health-based screening values are derived from epidemiological data demonstrating a direct, quantitative relationship between biomarker measurement and adverse health effects. Indeed, only a few substances (e.g. lead and mercury) have these health-based screening values because their development is highly resource and time intensive ). Consequently, the biomonitoring equivalent (BE) approach was developed by Hays et al. (2007) as an interim tool for interpreting population level biomonitoring data in a health risk context (Hays et al., 2007) . A BE is the concentration of a biomarker of exposure for an environmental chemical in a biological medium (e.g. blood, urine) consistent with an existing exposure guidance value for that chemical (Hays et al., 2008a; LaKind et al., 2008) . Exposure guidance values for non-cancer health effects include reference doses (RfD) from the U.S. Environmental Protection Agency (US EPA) and tolerable or acceptable daily intakes (TDI or ADI) from Health Canada. Cancer-based exposure guidance values include the risk-specific dose (e.g. dose associated with a 10 −4 cancer risk from Health Canada) based on oral cancer slope factor or inhalation unit risk derived for different chemicals. This study also utilized other screening values such as human biomonitoring-I (HBM-I) values from the German Human Biomonitoring Commission for thallium, perfluorooctane sulfonate (PFOS) and perfluorooctanoic acid (PFOA) and biomonitoring guidance values (BGVs) for chlorpyrifos (Apel et al., 2017; Arnold et al., 2015; Steckling et al., 2018) . HBM-I values are derived based on epidemiological data on human toxicity and, more recently, using internationally accepted TDI/RfD values or toxicologically well-founded points of departure observed in animal studies (Apel et al., 2017; Schulz et al., 2011) . The BGVs for chlorpyrifos are not based upon existing exposure guidance values, but rather use physiologically based pharmacokinetic (PBPK) and pharmacodynamic models to predict levels of biomarkers that are an early indicator of adverse health effects (Arnold et al., 2015) . In this article, we use the terminology "biomonitoring screening values" to encompass all of these values (BE, HBM-I, BGV).
Biomonitoring screening values are tools that can be used for rapid screening of chemical biomonitoring data to identify exposures of concern and can contribute to ranking of chemical priorities for risk assessment and evaluation of risk management actions.
Previously, St-Amand et al. (2014) screened the CHMS populationlevel data from 2007 to 2009 and 2009-2011 in a risk-based context using BE values. The study suggested that exposures to most of the environmental chemicals assessed, except for inorganic arsenic and cadmium, were below existing exposure guidance values. Since this initial study, additional cycles (2012) (2013) (2014) (2015) of CHMS data have been released providing more recent biomonitoring data for a number of chemicals included in St-Amand et al. (2014) , and data for additional chemicals not measured in earlier cycles. New or updated exposure guidance values and/or biomonitoring screening values have also recently been published for some of the chemicals measured as part of the earlier cycles of CHMS (e.g., silver, fluoride, PFOS, and PFOA). Consequently, this study aims to provide an updated interpretation of population level CHMS biomonitoring data in a health risk based context using a set of biomonitoring screening values in order to identify chemicals for which current levels of exposure could be a concern.
Methods
The following sections describe the criteria used in the selection of CHMS biomonitoring data for analysis, relevant biomonitoring screening values and, finally, the approach used in the risk-based screening of population-level biomonitoring data.
Selection of biomonitoring data
Biomonitoring data from the CHMS are representative of the general population aged 6-79 years for 2007-2009, and 3-79 years for 2009-2011, 2012-2013 and 2014-2015 . An overview of the biomonitoring component of the CHMS as well as a complete list of chemicals measured between 2007 and 2015 are provided in Haines et al. (2017) . All chemicals measured in the most recent cycle (2014) (2015) with an existing biomonitoring screening value were included in this study, except for bromoform and tetrachloroethylene for which the cycle 3 (2012-2013) data were used due to a low detection rate or high coefficient of variation (CV) in Cycle 4. Chemicals measured in cycle 1 or 2 only and for which new biomonitoring screening values have been published since 2014 or for which an updated BE could be calculated based on a new exposure guidance value were also included in this study. These chemicals include cyfluthrin, deltamethrin, molybdenum, selenium, silver, thallium, 2,4-dichlorophenoxyacetic acid (2,4-D), 3phenoxybenzoic acid (3-PBA), PFOS and PFOA.
Biomonitoring screening values developed for non-cancer endpoints were compared to the geometric mean (GM) and 95th percentile (P95) concentrations from the CHMS for the general Canadian population (Tables 1-3) (Health Canada, 2013 Canada, , 2015b 2017c) . For some chemicals, evaluation was conducted using age-specific data, when screening values were derived for specific age groups (fluoride and chlorpyrifos) or when bioaccumulation with age is expected due to long elimination half-lives of the biomarkers (cadmium, PFOA and PFOA). For some chemicals, evaluations were conducted for smokers and non-smokers when evidence shows impact of smoking on blood or urinary concentrations as in the cases of acrylamide, cadmium, toluene, benzene, ethylbenzene, xylene and styrene (Health Canada, 2017c; Kirman et al., 2012) . Statistical estimates for subpopulation of smokers and nonsmokers as well as specific age-groups not available as part as CHMS biomonitoring reports were calculated de novo for this exercise. For calculation of cancer risk estimates, population percentiles (P5, P25, P50, P75, and P95) were calculated for smokers and non-smokers for benzene and acrylamide in blood, and for the total population for inorganic arsenic in urine (Table 4 ). Cancer risk analysis by smoking status was carried out for benzene and acrylamide based on evidence that biomonitoring data for these chemicals may be impacted by smoking (Health Canada, 2017c; Kirman et al., 2012) . A urinary cotinine concentration cut-off of 50 ng/ml was used to define smokers (≥50 ng/ml) and non-smokers (< 50 ng/ml) (SRNT, 2002) . The glycidamide haemoglobin adduct (GAVal) biomarker may be more critical than the parent compound for carcinogenic properties and, therefore, was used to assess cancer risks associated with exposure of acrylamide (EPA, 2010). For the purpose of this analysis, concentration of (2009-2011) 6-79 5575 190 (190-190) 240 ( inorganic arsenic was calculated as the sum of inorganic-arsenic exposure related urinary metabolites, viz. arsenate, arsenite, dimethylarsinic acid (DMA) and monomethylarsonic acid (MMA). Statistical estimates (GMs and percentiles of population concentration) for which the CV was between 16.6% and 33.3% are considered to have high sampling variability and caution is recommended when using these data (Health Canada, 2017c) . To indicate that these data should be used with caution, these estimates are flagged in data tables, and data points based upon these estimates are marked with the plus (+) symbol in figures. When the CV for an estimate is greater than 33.3%, the value is considered unreliable and is therefore not interpreted using the biomonitoring screening values. GMs were not calculated when greater than 40% of measurements were below the limit of detection (LOD) and, in these cases, the assessment is based solely on the P95. In the calculation of statistical estimates, values below LOD were assigned a value of LOD/2. The estimates were calculated using the Statistical Analysis System (SAS) software and SUDAAN® statistical software package.
Selection and updating of biomonitoring screening values
The general methods for deriving BE and HBM-I values have previously been described (Hays et al., 2008a; Apel et al., 2017) , and chemical specific derivations of various biomonitoring screening values are as reported in publications referred to in Tables 1-4.
Biomonitoring equivalents
In our analysis, BE values were preferred to other biomonitoring screening values when available. For the underlying exposure guidance values, preference was given to those from Health Canada, followed by those from the US EPA. However, in some cases, the exposure guidance value was chosen based on the most relevant route of exposure. Blood screening values derived using the BE approach are available for volatile organic compounds (VOCs) such as toluene and ethylbenzene. These blood screening values, derived in absence of specific PBPK model for several VOCs, are defined as the estimate of chemical specific steady-state blood concentrations associated with chronic oral and inhalation exposure at the corresponding US EPA RfD or Health Canada TDI concentrations . Within this study, they are referred to as BE values. BE values based upon risk specific doses (RSD) from cancer risk assessments (i.e. BE RSD ) are available for acrylamide, arsenic and benzene. Since the St-Amand et al. (2014) study, an updated BE was published for 2,4-dichlorophenoxyacetic acid. In addition, BE values were recalculated for chemicals where the underlying exposure guidance values (e.g. RfD, TDI/ADI) have been revised since the original screening value publication (see details in Tables 1-4 ). These chemicals include molybdenum, cyfluthrin, deltamethrin, triclosan, GAVal, toluene, xylene and ethylbenzene.
Other biomonitoring screening values
HBM-I values were used for thallium and for the perfluoroalkyl substances, perfluorooctane sulfonate (PFOS) and perfluorooctanoic acid (PFOA) (Apel et al., 2017; Steckling et al., 2018) . In the assessment of chlorpyrifos, the BGVs developed by Arnold et al. (2015) were used. These values represent the levels of urinary biomarker (3,5,6-trichloro-2-pyridinol, TCPy) for chlorpyrifos at which 10% of red blood cell cholinesterase inhibition is predicted to occur in 95% of a population following acute oral exposure.
Calculation of hazard quotients
For non-cancer endpoints, hazard quotients (HQ) were calculated as the ratio of the biomarker concentration, at the GM or P95, to the chemical-specific biomonitoring screening value: A new BE was calculated using a recent NOAEL adopted by Health Canada (Health Canada, 2016), methodology as described previously , and a UF of 100. c A new BE was calculated using a recent Health Canada ADI (Health Canada, 2017g), methodology as described previously , and a UF of 300 applied to the POD.
d If > 40% of samples were below the limit of detection, the GM was not calculated. e A new BE was calculated using a recent Health Canada ADI (Health Canada, 2015a), methodology as described previously , and a UF of 300 applied to the POD.
f
The BE was updated since the previous CHMS screening analysis (St-Amand et al., 2014) to reflect changes made to the US EPA assessment.
g Data are too unreliable to be published. h A new BE was calculated using a recent ECCC and HC ADI (ECCC and HC, 2016), methodology as described previously (Krishnan et al., 2010b) , and a UF of 300 applied to the POD. i A new BE was calculated using a recent US EPA RfD (US EPA, 2010), methodology as described previously ) and a UF of 10 applied to the POD. Data should be used with caution as coefficient of variation is between 16.6% and 33.3%. c A new BE was calculated using a recent Health Canada Air Guidance value (Health Canada, 2011), methodology as described previously and applying an UF of 10 to the POD. d A new BE was calculated using a recent Health Canada TDI (Health Canada, 2014), methodology as described previously and applying an UF of 25 to the POD. e A new BE was calculated using a recent Health Canada TC (Health Canada, 1996) , methodology as described previously and applying an UF of 1000 to the POD. S. Faure, et al. International Journal of Hygiene and Environmental Health xxx (xxxx) A new BE RSD was calculated using a recent US EPA oral cancer slope factor (US EPA, 2010), methodology as described previously HQs near or exceeding a value of 1 suggest that exposure levels in the population are near or exceeding existing exposure guidance values.
BE values based upon risk specific doses at a risk level of 1 × 10 −4 from cancer risk assessments (i.e. BE RSD ) were used in the calculation of cancer risk estimates corresponding to population exposures at the P5, P25, P50, P75 and P95 percentile using the equation below:
Cancer risk = ([biomarker] / BE RSD ) x 10 −4
(2)
BE RSD values provide an estimate of the steady-state concentrations in blood or urine that would result from chronic exposure, over a lifetime, at the risk specific doses. Linear extrapolation was assumed in the calculation of cancer risk estimates. Cancer risks exceeding 1 × 10 −5 indicate that exposure levels may be exceeding the risk considered negligible by Health Canada (Health Canada, 2010a) , and the substance involved should be considered as a priority for further evaluation.
Large variation in the blood or urinary concentrations of chemicals can be expected over the course of a day (intra-individual) or between individuals for highly transient chemicals such as VOCs and those described as non-persistent in this study (e.g. fluoride has a half-life of urinary elimination of approximately 6 h) Gurusankar et al., 2017) . Consequently, for these chemicals, the tails of the concentration distribution (i.e. P5 and P95) may not be indicative of long-term exposure levels but rather transitory periods of low or high exposures. An evaluation of the central tendency of the population (GM) is more relevant for these chemicals as it allows more meaningful interpretation of population exposures (Aylward et al., 2013) .
Results
Chemicals assessed using biomonitoring screening values based on non-cancer endpoints are shown in Table 1 (non-persistent chemicals), 2 (persistent chemicals) and 3 (volatile organic compounds). For each chemical, the tables present summary statistics from the CHMS for a relevant biomarker (parent chemical, metabolite or sum of metabolites), the exposure guidance value and the corresponding biomonitoring screening value, and references. Cancer reference values for known carcinogens measured as part of the CHMS (e.g. oral cancer slope factors, inhalation unit risk) along with population statistics relevant to the calculation of cancer risks are presented in Table 4 .
Hazard quotients for non-cancer endpoints

Non-persistent chemicals
The HQ values at the GM and P95 concentrations for non-persistent chemicals in the Canadian population are presented in Fig. 1 . For this exercise, a chemical was defined as non-persistent when its elimination half-life is relatively short (e.g., less than a day for some chemicals excreted in urine, or somewhat longer as in the case of the blood biomarkers of acrylamide (i.e. concentration of acrylamide hemoglobin adducts limited by the rate of red blood cell turnover)). Of the 14 nonpersistent chemicals assessed, only four had HQ values greater than one at P95, namely fluoride, inorganic arsenic, 3-PBA and acrylamide. The HQs for fluoride in 3-5 and 6-11 year olds, calculated using the agespecific BE value , slightly exceeded 1 at the P95 (1.23 and 1.07, respectively, for the two age groups) but not at the GM. The P95 estimate for 3-5 year olds has been flagged for high variability and, as such, caution is required when using this data. No exceedances were observed in the older age groups. For inorganic arsenic, the calculated HQ for 3-79 year olds at the GM was near one (0.797) while the HQ at the P95 exceeded one (3.13). For 3-PBA, a common metabolite of various pyrethroid pesticides, two screening-level BE values have previously been derived (Aylward et al., 2018) . The tier 1 value of 1.7 μg/L in urine is highly conservative based on an assumption that all urinary 3-PBA is derived from an exposure to a pyrethroid pesticide with the most stringent exposure guidance value and the tier 2 value of 87 μg/L is less conservative but might be more realistic as it was derived based on a weighted relative exposure to different pyrethroid compounds (Aylward et al., 2018) . For the tier 1 BE only, the HQ value exceeded 1 at the P95 (3.41, flagged for high variability) but not at the GM (0.25). Finally for acrylamide, which was assessed by comparing levels of two of its metabolites in blood, namely acrylamide haemoglobin adduct (AAVal) and glycidamide haemoglobin adduct (GAVal), HQs exceeded 1 for both biomarkers in smokers aged 3-79 years at the P95 (1.53 and 1.42, respectively for AAVal and GAVal). These exceedances were not seen in non-smokers for either biomarker.
Persistent chemicals
The HQ for persistent chemicals is shown in Fig. 2 . In this analysis, HQs for cadmium at both the GM and P95 increased with age and were higher in smokers than non-smokers. Age-dependent increases in cadmium levels in the Canadian population have been noted previously for data from 2007 to 2009 and 2009-2011 of the CHMS (Garner and Levallois, 2016) . For cadmium, non-smokers HQ values were below 1 while for smokers, HQ values exceeded 1 for all age groups at the GM (1.06-1.18) and P95 (1.65-3.18) with the exception of the GM for the youngest age group of 12-19 years included for these chemicals (0.35). The GM estimate for the aged group 12-19 years and the P95 estimate for the age groups 40-59 years are flagged for high variability and, as such, caution is required when using this data. For PFOA, HQs for all age groups were above 1 at the GM (1.05-1.40) and P95 (2.05-3.20) . For PFOS, all HQs were above 1 at the GM (1.24-1.88), except the HQ for the youngest age group of 12-19 years (0.92). All HQs at the P95 (2.20-4.20) were above 1, with HQs for age groups 20-39 years and 60-79 years flagged for high variability.
Volatile organic compounds
The HQ values at the GM and P95 for VOCs in the Canadian population are presented in Fig. 3 . All eight of the VOCs screened in this study had an HQ value below 1 at both the GM and P95 concentration with the exception of benzene in smokers. For this chemical, the HQ value at the GM for smokers approached 1 (0.93), and exceeded 1 at the P95 (2.80).
Cancer risks
The cancer risks for various percentiles of concentration in the Canadian general population (P5, P25, P50, P75 and P95) for biomarkers of acrylamide, inorganic arsenic and benzene are presented in Fig. 4 . Most of the cancer risks calculated for these compounds were above the range of 10 −5 to 10 −6 considered to be essentially negligible risk (Health Canada, 2010a) . Cancer risks calculated at different concentration percentiles for the acrylamide biomarker GAVal in nonsmokers were close to 10 −3 (ranging from 5.12 × 10 −4 at P5, flagged with high variability, to 2.25 × 10 −3 at P95). Cancer risks in smokers were higher (ranging from 7.99 × 10 −4 at P5 to 5.12 × 10 −3 at P95). For inorganic arsenic, cancer risk estimates were above the negligible risk range at all percentiles of the population assessed (ranging from 1.4 × 10 −4 at P5, flagged for high variability to 1.4 × 10 −3 at P95). Two BE RSD were used for benzene corresponding to the lower bound and the upper bound of the cancer exposure guidance value range derived by the US EPA. For benzene in non-smokers, all of the cancer risks are above the range of negligible risks with the exception of the P25 (6.36 × 10 −6 ) when evaluated with the BE RSD at upper bound which is the less conservative value. Caution is required when interpreting the cancer risks for benzene in non-smokers calculated at the P25, P50 and P75 due to high variability in the biomonitoring data. For benzene in smokers, cancer risks exceeded the negligible range when evaluated with the upper bound BE RSD (ranging from 1.42 × 10 − 5 at P5 and 2.06 × 10 −4 at P95) and with the lower bound BE RSD (ranging from 4.97 × 10 − 5 at P5 to 7.20 × 10 −4 at P95). Caution is required when interpreting the cancer risks for benzene in smokers calculated at the P5 due to high variability in the biomonitoring data.
Discussion
Screening of biomonitoring data
This study analyzed CHMS biomonitoring data from various cycles in a health risk-based context building on the work of St-Amand et al. (2014) . The current study continues the risk screening using more recent biomonitoring data and updated biomonitoring screening values.
For non-cancer endpoints, 17 of the 25 chemicals analyzed had HQs of less than 1 both at GM and P95 concentrations suggesting that exposure of the general population to these chemicals is occurring at levels below the current exposure guidance values. Specifically, the GM (or P95 when no GM is available) concentrations for eleven of these chemicals were 10-100 000 times lower than their respective BE values (HQs between 0.1 and 0.00001 for molybdenum, thallium, cyfluthrin, deltamethrin, chlorpyrifos, 2,4-D, BPA, bromoform, toluene, styrene, and tetrachloroethylene) and the HQs at the GM (or P95 when the GM is not available) for the other six chemicals fell between 1 and 0.1 (selenium, silver, triclosan, chloroform, xylenes and ethylbenzene). HQs exceeded 1 at the GM and/or P95 concentrations for eight BE RSD used for benzene correspond to the lower bound (BE RSD L) and the upper bound (BE RSD U) of the cancer exposure guidance value range derived by the U.S. EPA. Medians are represented by the horizontal lines; boxes extend to the 25th and 75th percentiles, and whiskers extend to the 5th and 95th percentiles. Abbreviations: +: HQ is to be used with caution as coefficient of variation is between 16.6% and 33.3%, BE RSD : Biomonitoring equivalent at risk specific dose, BE RSD L: BE RSD at lower bound, BE RSD U: BE RSD at upper bound, DMA: Dimethylarsinic acid, iAs: inorganic arsenic, MMA: Monomethylarsonic acid. chemicals, namely fluoride, inorganic arsenic, 3-PBA, PFOA, and PFOS in the general population and acrylamide, cadmium, and benzene in smokers. These results indicate that exposure to these substances in the general and/or smoking Canadian population could be exceeding their respective exposure guidance values. In this study, cancer risks for benzene, acrylamide and inorganic arsenic in the general population fell above the range defined as essentially negligible (10 −5 -10 −6 ) (Health Canada, 2010a) .
BE values are applied with an assumption of chronic exposure, however for biomarkers with short half-life such as fluoride, large variations in concentrations can be expected within an individual over the course of a day. Consequently, high exposures represented by the P95 are not necessarily indicative of continuous exposure for non-persistent chemicals, particularly when measured in spot urine samples. Rather, for non-persistent chemicals, the upper bound of exposure may be more reflective of a transient peak of exposure and the central tendency (GM or P50) is more informative of long term exposure Gurusankar et al., 2017) . In this study, this is relevant for fluoride, inorganic arsenic, 3-PBA and benzene for which biomarkers are rapidly eliminated and HQs at the GM are under 1. However, as the size of the sample in this analysis is large, it may be interesting to explore whether the P95 may actually be reflective of high level exposures to chemicals with short-elimination half-lives. Indeed, an examination of the CHMS biomonitoring data for short-lived chemicals demonstrates consistency of estimates across cycles at the tail of the population exposure, suggesting potential validity of use of the upper percentile estimates for short-lived chemicals in large population studies. For example, P95 concentrations of urinary BPA in cycles 1, 2, 3 and 4 are 6.9 μg/L, 6.7 μg/L, 6.6 μg/L and 6.0 μg/L, respectively. For substances with biomarkers having a longer half-life such as acrylamide, cadmium and perfluoroalkyl substances (PFOA and PFOS) both HQs at the GM and P95 are informative of population exposure because their blood or urine levels are more likely to remain constant over the course of days or weeks.
Results from the 2014-2015 data are consistent with the previous assessment of the same chemicals using data from 2007 to -2011 . For example, St-Amand et al. (2014 identified exceedances of cadmium and inorganic arsenic concentrations over their respective biomonitoring screening values. The current results can also be compared with other national biomonitoring data screening studies such as those conducted on data from the U.S. National Health and Nutrition Examination Survey (NHANES). An interpretation of NHANES data from 2013 using BE values resulted in similar findings to those of St-Amand et al. (2014) and the present work. For example, HQs for inorganic arsenic exceeded 1 at the P95 concentration for the U.S. general population. HQs for acrylamide, cadmium and benzene also exceeded 1 at the P95 for smokers based on NHANES. Similar to our findings on cancer risks based on Canadian data, cancer risks in the U.S. population exceeded the 1 × 10 −5 cancer risk level for benzene and acrylamide in both smokers and non-smokers, and inorganic arsenic in the general population (Aylward et al., 2013) .
For the chemicals trichloroethylene, bromodichloromethane and dibromochloromethane measured in 2014-2015 of the CHMS, GM and P95 calculations were not possible due to low detection (i.e., more than 95% of measurements were below the LOD). Therefore, while BE values are available for these chemicals, it was not possible to calculate HQ values. Nevertheless, BE values for these chemicals are higher than their respective LODs. The low detection of these chemicals combined with the LODs being lower than the respective BE values indicates that exposures in the general population are below the current level of concern.
Finally, HQs greater than 1 at the GM or P95 for acrylamide, benzene, cadmium, fluoride, inorganic arsenic, 3-PBA, PFOA and PFOS, as well as cancer risks exceeding the range defined as essentially negligible (10 −5 -10 −6 ) for benzene, acrylamide and inorganic arsenic suggest that these chemicals should remain as priorities for continued biomonitoring. For these chemicals, this screening exercise also provides evidence to support the findings of past risk assessments resulting in a number of risk management and mitigation measures implemented by Health Canada. Risk assessments under the Canadian Environmental Protection Act, 1999 (CEPA, 1999 have resulted in the listing of acrylamide, benzene, cadmium (inorganic), fluoride, inorganic arsenic, PFOA and PFOS on Schedule 1, List of Toxic Substances (Canada, 1999; Canada, 2018) . The Act allows the federal government to control the importation, manufacture, distribution, and use of these chemicals in Canada. Accordingly, Health Canada has carried out a number of recent activities for these substances to reduce population exposure including proposed updates to the maximum levels of arsenic in apple juice and water in sealed containers, new guidelines for PFOS and PFOA in drinking water, and a health risk assessment of dietary cadmium (ECCC, 2016; Health Canada, 1996 , 2017a , 2017b , 2017e, 2017d , 2018a , 2018b , 2018c . In addition, acrylamide, cadmium and inorganic arsenic have also recently been identified for further scoping to find new potential sources of exposure to assess and manage on the basis of previous screening activities with CHMS data including those by St-Amand et al. (2014) (ECCC and HC, 2019) . Under the Pest Control Products Act (PCPA) (Canada, 2006b) , various pyrethroid pesticides, for which 3-PBA is a metabolite, have been evaluated including reevaluations of lambda-cyhalothrin and cypermethrin (Health Canada, 2017f, 2018d . A number of these mitigation measures have been implemented since the release of latest cycle of CHMS data (2014) (2015) that have been used in the current analyses. These measures along with future studies and assessments and the ongoing collection of human biomonitoring data as part of the CHMS will help contribute to a better understanding of the potential health risks posed by these chemicals in the Canadian population.
Limitations of BE values and alternate screening approaches
Some limitations of this study are inherent to the use of BE values and other biomonitoring screening values. A number of these limitations, including the interim approach behind the derivation of these values, their population rather than individual purpose, as well as the lack of tools for the assessment of multi-pollutant exposures, are described elsewhere (Aylward et al., 2013; Kirman et al., 2012; St-Amand et al., 2014) . An important limitation to this study is the absence of biomonitoring screening values for a number of chemicals measured in the CHMS including chlorophenols and neonicotinoid pesticides. This underpins the fact that our ability to monitor chemicals in humans exceeds our ability to interpret these data in a health risk context and that other ways to interpret risks posed by chemicals are required. Screening values can be challenging to derive due to limited experimental data or pharmacological models and the lack of a clear understanding of the mode of action for many environmental chemicals. Nevertheless, a number of BE values are currently being developed by Health Canada including for parabens and malathion.
Another limitation which has to be considered when interpreting the results is the fact that confidence in BE values can vary from one chemical to another. This confidence is based on biomarker specificity or relation of this biomarker to dose metrics associated with the endpoints of interest and the robustness of pharmacokinetics models. For example, confidence based on biomarker specificity is high for the AAVal and GAVal BE values . In contrast, the confidence is only low to medium for the cyfluthrin BE as the biomarker is not directly related to the mode of action of this substance . Low biomarker specificity can lead to overestimation of the risks. For example, caution is required when interpreting data for biomarkers of inorganic arsenic and pyrethroid pesticides. In the case of inorganic arsenic, the concentration of DMA, the most detected urinary arsenic metabolite, drives the sum of the concentrations of inorganicderived arsenic species calculated for this analysis. However, levels of urinary DMA has also been associated with direct consumption of DMA contained in foods such as rice and seafood, and DMA derived from the metabolism of arsenolipids and arsenosugars contained in seafood . Consequently, the exposure to inorganic-derived arsenic as calculated in this study might be overestimated. In the case of 3-PBA, exceedances of the BE value are only observed when using the tier 1 BE value, which is based on a conservative assumption that all urinary 3-PBA arises from exposure to the most potent pyrethroid compound. A tier 2 BE value for 3-PBA is available which takes into account the estimated proportional contributions of several pyrethroids to an exposure (Aylward et al., 2018) . When the tier 2 value is used, the HQ values fall below 0.1 (Fig. 1) . Confidence in the pharmacokinetic models used in the development of a BE can be robust as for molybdenum, given that a method based on data from a study using several different daily doses of molybdenum and conducted in a controlled metabolic research station is used to convert a daily dose of molybdenum to urinary excretion rate, or less robust as for deltamethrin for which a urinary BE is derived based on a dataset from a study using only a single oral dose Hays et al., 2016) .
Not only are the biomarkers and pharmacokinetic models important for confidence in a BE, but also are the exposure guidance value that were used to derive the BE. These values and associated confidence can also differ greatly between regulatory agencies due to differences in studies used, points of departure and uncertainty factors. Consequently, each BE will be only as strong as the exposure guidance value on which it is based. For example, several BE values exist for benzene including the value of 0.15 μg/L used in this study based on a US EPA assessment and a less conservative value of 0.29 μg/L based on a California Reference Exposure Level. The major difference was the use of two different human studies with different endpoints of interest . Although BE values are used here only to identify chemicals that may require further evaluation, recent risk assessments have used biomonitoring screening values alongside biomonitoring data from the CHMS to evaluate risks to human health (Health Canada, 2018e; Zidek et al., 2017) . Such uses exist for several chemicals including four assessed in this study namely selenium, thallium, molybdenum and silver (Health Canada, 2016) . Therefore, the increasingly broad use of BE values demonstrates a need to continue to improve the accuracy and relevance of these values based on available exposure guidance values and pharmacokinetic data. More recently, Phillips et al. (2014) proposed a stochastically based Monte Carlo approach for calculating a distribution of BE values for a chemical taking into account the variability in physiology and pharmacokinetics at different exposure levels. A distribution of BE values rather than a single BE may be a more useful tool to more appropriately evaluate both the central tendency and the tail (e.g. 95th percentile) of a population distribution of biomonitoring data, especially for short-lived chemicals where higher biomonitoring concentrations may reflect elevated acute or chronic exposures or simply the timing of exposure with respect to sample collection.
Chemicals assessed here for cancer risk are classified by the International Agency for Research on Cancer (IARC) as group 1 (carcinogenic to humans, arsenic and benzene) or group 2A (probably carcinogenic to humans, acrylamide). Nevertheless, it is important to consider some uncertainties associated with cancer risk estimation using screening values derived based on cancer slope factors. Firstly, the slope factors or unit risks associated with lifetime exposure to a chemical may themselves vary between different agencies (e.g. US EPA, Health Canada). Further, the cancer slope factors or unit risks have been arrived at using linear models in conjunction with a low-dose extrapolation approach. Whereas this is an accepted approach for the estimation of cancer risks, it is plausible that the uncertainties associated with the shape of dose response or mode of action at low-doses may potentially affect results including possible overestimation or underestimation of the risks. Considering the uncertainty associated with low-dose cancer risk extrapolation, a margin of exposure approach that uses a point of departure such as the benchmark dose (BMD) associated with a low, measurable (e.g. 10% increase over background cancer incidence) response in an experimental or epidemiological study is gaining significance in the assessment of cancer risks for genotoxic, non-threshold carcinogens.
Future work
This type of analysis provides useful evidence for risk assessors and risk managers for further assessment and/or follow-up related to the assessment and management of chemical exposures. In this sense, continued screening of CHMS data when new biomonitoring screening values and/or new biomonitoring data are available is required. Ongoing revisions to environmental and dietary questionnaires in CHMS to better capture exposure sources will augment follow-up activities including re-evaluation and mitigation of exposures.
It would also be interesting to analyse the risk posed by combined exposure of chemicals with chemical-specific biomonitoring screening values. For example, the Hazard Index is an approach assuming dose addition in tissues and used in an assessment of VOC data from NHANES by Aylward et al. (2013) and Kirman et al. (2012) . A similar exercise can be done with CHMS chemicals that have known interactions and shared end-points; and this could provide further information to support regulatory evaluation. Benzene is an example of a chemical for which this exercise may be of use as it has HQs above 1 and is known to interact with other organic volatile compounds such as toluene, xylene and ethylbenzene (Haddad et al., 1999) .
Conclusion
This study provides a unique assessment of chemical exposures in a health risk based context at the population level in Canada using the most recent CHMS biomonitoring data. It is a rapid screening approach to identify environmental chemicals to which the general population may be exposed at levels near or exceeding existing risk assessmentbased exposure guidance values. This presents an additional layer of exposure-based prioritization building upon the original prioritization process carried out when the chemicals were initially selected for inclusion in the CHMS. Consequently the identified chemicals can be seen as priorities for advanced examination including investigation of sources and pathways of exposure. This may subsequently lead to targeted actions to eliminate and mitigate exposure sources and reduce associated health risks. As many regulatory actions are underway or have already been implemented for these chemicals, this study also provides evidence to support these actions. The ongoing collection and screening of human biomonitoring data from the CHMS will help track exposures to these priority chemicals in the Canadian population and support the ongoing work to mitigate exposures and reduce health risks.
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